You are here

Theranos Dumps Finger-Stick Blood Tests, Closes Testing Sites

Company to focus on printer-sized miniLabs

Embattled Theranos, Inc., has decided to close its blood-testing facilities and reduce its workforce by more than 40%, according to a report in the Wall Street Journal (WSJ).

In a statement posted on the company’s website, founder Elizabeth Holmes said: “We will return our undivided attention to our miniLab platform. Our ultimate goal is to commercialize miniaturized, automated laboratories capable of small-volume sample testing, with an emphasis on vulnerable patient populations, including oncology, pediatrics, and intensive care.”

Holmes announced the miniLab blood-testing device in August at a conference of laboratory scientists. She said the device, which is about the size of a printer, could run accurate tests from a few drops of blood. 

Theranos was hit by crippling regulatory sanctions following revelations by the WSJ of shortcomings in the company’s blood-testing technology and operations. In October 2015, the WSJ  detailed concerns about the company’s testing accuracy. Theranos later voided all results from its proprietary testing device for 2014 and 2015.

The company also faces federal criminal and civil investigations into whether it misled investors.

In June 2016, Walgreens closed all of the blood-collection locations it had opened in a Theranos partnership.

Holmes’ website statement also indicated that her company’s “restructuring” would affect “approximately 340 employees” in Arizona, California, and Pennsylvania. In early August, Theranos claimed to have 790 employees.

Sources: Wall Street Journal; October 6, 2016; and Theranos, Inc.; October 5, 2016.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
One in Five Kids’ Office Visits Results in an Off-Label Rx
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs